CERO stockholders approve reverse stock split (1:40–1:150) and 32M share increase to equity plan

CERO THERAPEUTICS HOLDINGS, INC.

Reverse stock split ratio set by board at not less than 1:40 or more than 1:150; approved with 8,012,563 for, 2,287,082 against.
Issuance of common shares upon conversion of Series E preferred (Oct 2025 PIPE) approved; 3,304,540 for, 1,422,195 against.
Equity incentive plan share reserve increased by 32,000,000 shares to 32,123,494 total; approved with 2,568,408 for.
Quorum was 10,988,347 shares (52.82% of 20,802,671 outstanding) at the Dec 19, 2025 special meeting.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.